During the corresponding time, Bridgebio Pharma Inc recorded a revenue increase by 120.39 % year on year, sequentially revenue grew by 25.27 %. While revenue at the Bridgebio Pharma Inc 's corporate clients
Bridgebio Pharma Inc's Comment on Sales, Marketing and Customers
The text addresses regulatory statutes including the federal Anti-Kickback Statute, the False Claims Act, HIPAA, and HITECH. It focuses on compliance requirements applicable to healthcare benefit programs, healthcare providers, health plans, healthcare clearinghouses, and their business associates.
: The management of Autosomal Dominant Hypocalcemia Type 1 (ADH1), a rare genetic disorder characterized by hypoparathyroidism and associated calcium and magnesium imbalances, has been challenging. Recent developments in pharmacotherapy have offered new hope for affected patients. This article summarizes the positive results of the CALIBRATE Phase 3 clinical trial assessing the efficacy of encaleret, a novel calcilytic agent, in treating individuals with ADH1.Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by mutations in the calcium-sensing receptor (CaSR), leading to abnormal calcium homeostasis. Patients typically present with low serum calcium levels, elevated urine calcium excretion, and symptom...
In a groundbreaking development in the field of cardiology, the U.S. Food and Drug Administration (FDA) has officially approved Attruby (acoramidis), marking a significant milestone in the treatment of patients suffering from transthyretin amyloid cardiomyopathy (ATTR-CM). This approval heralds the emergence of Attruby as the first and only therapeutic agent with a designated label indicating near-complete stabilization of transthyretin (TTR) protein at an impressive 90% efficacy. ATTR-CM is a progressive and often fatal disease characterized by the accumulation of amyloid fibrils derived from misfolded TTR proteins in the heart, leading to debilitating cardiovascular symptoms. Traditional treatments have st...
BridgeBio to Unveil Key Data on Acoramidis for ATTR-CM at ESC Congress 2024 and HFSA Annual Meeting 2024 PALO ALTO, Calif. , Aug. 29, 2024 - BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company specializing in genetic diseases, is poised to provide new insights into the efficacy and safety of acoramidis, its promising therapeutic candidate for transthyretin amyloid cardiomyopathy (ATTR-CM). The additional data from the pivotal Phase 3 ATTRibute-CM trial will be presented at two major upcoming medical conferences: the European Society of Cardiology (ESC) Congress 2024 in London from August 30 to September 2, and the Heart Failure Society of America (HFSA) Annual Scientific Meet...
BridgeBio Pharma, a company known for its prowess in genetic medicine, has reached a significant milestone in the quest for effective treatments for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). Recently, the company announced that it has not only surpassed its interim analysis enrollment target for the Phase 3 FORTIFY study but also received the Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for BBP-418, a promising therapeutic candidate. LGMD2I/R9: A Rare and Debilitating Disease Limb-girdle Muscular Dystrophy Type 2I/R9 is a rare genetic disorder characterized by progressive weakness and wasting of the muscles, predominantly affecting the shoulders and hips. T...
Promising Outcomes from BridgeBio Pharma’s Clinical Trials: Effective Treatments for Achondroplasia and Transthyretin Amyloid CardiomyopathyBridgeBio Pharma is making significant strides in addressing rare genetic conditions, evidenced by the promising results from its ongoing clinical trials. Recent announcements underscore the company s commitment to providing effective treatments for conditions such as achondroplasia and transthyretin amyloid cardiomyopathy (ATTR-CM), highlighting both durable therapeutic benefits and robust safety profiles. Positive Results for Infigratinib in AchondroplasiaBridgeBio announced encouraging results from its Phase 2 PROPEL 2 trial, focusing on the Cohort 5 subgroup treat...
In a significant advancement for the treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM), recent data presented at the International Society of Amyloidosis (ISA) conference showcases the promising efficacy of Acoramidis. This Phase 3 study, known as ATTRibute-CM, conducted by BridgeBio Pharma, sheds new light on the profound impact of Acoramidis on cardiovascular health among patients afflicted with this debilitating condition.ATTR-CM is a progressive disease where misfolded transthyretin (TTR) proteins accumulate in the heart, leading to severe cardiac dysfunction and dramatically reduced life expectancy. Addressing this condition has proven challenging, which underscores the importance of this bre...
Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a rare and life-threatening disease characterized by the accumulation of amyloid fibrils in the heart, has seen limited therapeutic options until recently. However, a groundbreaking study, known as ATTRibute-CM, has demonstrated the potential of Acoramidis, a novel therapeutic agent developed by BridgeBio Pharma, to effectively treat this debilitating condition. This article provides a detailed analysis of the ATTRibute-CM study, its outcomes, and the implications for the future management of patients with ATTR-CM.Study Design and Methodology:The ATTRibute-CM study was a multicenter, double-blind, placebo-controlled Phase 3 trial that assessed the safety and ef...
BridgeBio Pharma recently presented additional data and analyses from its Phase 3 ATTRibute-CM study at the ESC-HF conference, shedding light on the remarkable potential of Acoramidis in treating Transthyretin Amyloid Cardiomyopathy (ATTR-CM). The study showcased a pre-specified sensitivity analysis, utilizing the entire intention-to-treat (ITT) population and highlighting the significant reduction in all-cause mortality. This article summarizes the key findings, analyzes their implications, and explores the potential impact on BridgeBio Pharma.BridgeBio Pharma s Phase 3 ATTRibute-CM study aimed to evaluate the efficacy and safety of Acoramidis in patients with ATTR-CM, a rare and life-threatening cardiac co...
In a groundbreaking partnership, BridgeBio Pharma and Bayer have recently announced a licensing agreement that will see Acoramidis, a potentially revolutionary therapy for transthyretin amyloid cardiomyopathy (ATTR-CM), brought to the European market. This collaborative effort holds significant promise for patients suffering from this rare and life-threatening genetic disease.Outline of Facts:1. BridgeBio grants Bayer exclusive rights: Through the licensing agreement, BridgeBio Pharma grants Bayer exclusive commercialization rights for Acoramidis in Europe as a treatment for ATTR-CM. This strategic partnership enables Bayer to leverage its extensive expertise and expansive market presence to effectively brin...
In a groundbreaking partnership, BridgeBio Pharma and Kyowa Kirin have joined forces to develop and commercialize infigratinib for the treatment of skeletal dysplasias in Japan. With an upfront payment of $100 million, this deal marks a significant development in the field of rare genetic disorders, with considerable implications for both companies involved.BridgeBio Pharma, a renowned biotechnology company specializing in genetic diseases, has announced a game-changing partnership with Kyowa Kirin, a leading Japan-based pharmaceutical company. The collaboration aims to address the urgent need for effective treatments for skeletal dysplasias, a group of rare genetic disorders characterized by abnormalities i...
Bridgebio Pharma Inc’s Comment on Sales, Marketing and Customers
The text addresses regulatory statutes including the federal Anti-Kickback Statute, the False Claims Act, HIPAA, and HITECH. It focuses on compliance requirements applicable to healthcare benefit programs, healthcare providers, health plans, healthcare clearinghouses, and their business associates.
Sources:
Bridgebio Pharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Bridgebio Pharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Bridgebio Pharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
165.4 %